KR100252547B1 - 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달 - Google Patents

폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달 Download PDF

Info

Publication number
KR100252547B1
KR100252547B1 KR1019940700741A KR19940700741A KR100252547B1 KR 100252547 B1 KR100252547 B1 KR 100252547B1 KR 1019940700741 A KR1019940700741 A KR 1019940700741A KR 19940700741 A KR19940700741 A KR 19940700741A KR 100252547 B1 KR100252547 B1 KR 100252547B1
Authority
KR
South Korea
Prior art keywords
cells
oligonucleotides
dna
cell
antisense
Prior art date
Application number
KR1019940700741A
Other languages
English (en)
Korean (ko)
Inventor
와이 우 죠오지
에이치 우 캐서린
Original Assignee
프레드 마리얀스키
더 유니버시티 오브 코넥티컷
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프레드 마리얀스키, 더 유니버시티 오브 코넥티컷 filed Critical 프레드 마리얀스키
Application granted granted Critical
Publication of KR100252547B1 publication Critical patent/KR100252547B1/ko

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3513Protein; Peptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1019940700741A 1991-09-05 1992-09-04 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달 KR100252547B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75508391A 1991-09-05 1991-09-05
US7/755,083 1991-09-05
US78811991A 1991-11-04 1991-11-04
US7/788,119 1991-11-04
US86400392A 1992-04-03 1992-04-03
US7/864,003 1992-04-03
PCT/US1992/007339 WO1993004701A1 (en) 1991-09-05 1992-09-04 Targeted delivery of poly- or oligonucleotides to cells

Publications (1)

Publication Number Publication Date
KR100252547B1 true KR100252547B1 (ko) 2000-09-01

Family

ID=27419474

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940700741A KR100252547B1 (ko) 1991-09-05 1992-09-04 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달

Country Status (6)

Country Link
EP (1) EP0666923A1 (ja)
JP (1) JPH07500820A (ja)
KR (1) KR100252547B1 (ja)
AU (1) AU681997B2 (ja)
CA (1) CA2116107A1 (ja)
WO (1) WO1993004701A1 (ja)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550561B1 (en) 1991-05-16 2009-06-23 Cold Spring Harbor Laboratory p16INK4 polypeptides
US5889169A (en) * 1991-05-16 1999-03-30 Cold Spring Harbor Laboratory Cell cycle regulatory protein p16 gene
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US6627615B1 (en) 1991-12-17 2003-09-30 The Regents Of The University Of California Methods and compositions for in vivo gene therapy
US5756353A (en) * 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5922859A (en) * 1992-02-01 1999-07-13 Boehringer Ingelheim International Gmbh Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
US6806084B1 (en) 1992-06-04 2004-10-19 The Regents Of The University Of California Methods for compositions for in vivo gene delivery
IL105914A0 (en) * 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
US5962316A (en) 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
EP0674705A4 (en) * 1992-11-09 1997-11-26 Univ Jefferson ANTISENSE OLIGONUCLEOTIDES USED TO INHIBIT THE EXPRESSION OF MUTATED AND WILD-LIKE COLLAGEN GENES.
US5574142A (en) * 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US6331390B1 (en) 1992-12-17 2001-12-18 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6043030A (en) * 1992-12-17 2000-03-28 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
WO1994016736A1 (en) * 1993-01-22 1994-08-04 University Research Corporation Localization of therapeutic agents
CA2159916A1 (en) * 1993-04-05 1994-10-13 Henry C. Chiou Targeted delivery of genes encoding antisense polyribonucleotides
EP0693939A1 (de) * 1993-04-14 1996-01-31 Roche Diagnostics GmbH Nukleinsäure-transferpeptide und deren verwendung zur einschleusung von nukleinsäuren in eukaryontische zellen
GB9317380D0 (en) * 1993-08-20 1993-10-06 Therexsys Ltd Transfection process
DE4331012A1 (de) * 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik
DE4331011A1 (de) * 1993-09-13 1995-03-16 Bayer Ag Nukleinsäuren-bindende Oligomere mit C-Verzweigung für Therapie und Diagnostik
US7691632B2 (en) 1993-11-18 2010-04-06 Cold Spring Harbor Laboratory Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
US5728518A (en) * 1994-01-12 1998-03-17 The Immune Response Corporation Antiviral poly-and oligonucleotides
AU1925195A (en) 1994-02-22 1995-09-04 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
AU2589695A (en) * 1994-05-13 1995-12-05 Chiron Corporation Compositions and methods for targeting gene delivery vehicles
FR2721612B1 (fr) * 1994-06-23 1996-08-09 Idm Nouveaux dérivés d'oligosides, leur procédé de préparation et leurs applications.
US5728399A (en) * 1994-06-29 1998-03-17 University Of Conn. Use of a bacterial component to enhance targeted delivery of polynucleotides to cells
DE4427980A1 (de) * 1994-08-08 1996-02-15 Bayer Ag Nukleinsäuren-bindende Oligomere für Therapie und Diagnostik
AU4690596A (en) * 1994-12-30 1996-07-24 Chiron Viagene, Inc. Nucleic acid condensing agents with reduced immunogenicity
AU5259796A (en) 1995-02-10 1996-08-27 Worcester Foundation For Biomedical Research, Inc. Delivery of exogenous compounds
WO1996030386A1 (fr) * 1995-03-31 1996-10-03 Drug Delivery System Institute, Ltd. Derives d'amidite et derives d'oligonucleotides
US5856459A (en) * 1995-06-06 1999-01-05 Hybridon, Inc. Oligonucleotides specific for hepatitis B virus
ATE466948T1 (de) 1997-03-11 2010-05-15 Univ Minnesota Dns-basiertes transposon-system für die einführung von nucleinsäure in die dns einer zelle
US6524613B1 (en) 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
CA2291074C (en) 1997-05-21 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
WO1998055611A1 (en) * 1997-06-06 1998-12-10 Regents Of The University Of Michigan Neuregulin response element and uses therefor
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
EP1019511A2 (en) 1997-10-01 2000-07-19 Dana-Farber Cancer Institute STABILIZATION OF ENVELOPE GLYCOPROTEIN TRIMERS BY DISULFIDE BONDS INTRODUCED INTO A gp41 GLYCOPROTEIN ECTODOMAIN
EP1053355B1 (en) * 1998-02-11 2001-11-14 PE Corporation (NY) Pna and dna conjugates and methods for preparation thereof
US6210892B1 (en) * 1998-10-07 2001-04-03 Isis Pharmaceuticals, Inc. Alteration of cellular behavior by antisense modulation of mRNA processing
US7160682B2 (en) 1998-11-13 2007-01-09 Regents Of The University Of Minnesota Nucleic acid transfer vector for the introduction of nucleic acid into the DNA of a cell
DE19858005B4 (de) * 1998-12-16 2007-02-08 november Aktiengesellschaft, Gesellschaft für Molekulare Medizin Synthetisches Nucleinsäure-Partikel
EP1210121A2 (en) 1999-08-24 2002-06-05 Cellgate Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6271360B1 (en) 1999-08-27 2001-08-07 Valigen (Us), Inc. Single-stranded oligodeoxynucleotide mutational vectors
DE69923840T2 (de) * 1999-09-09 2006-04-06 Curevac Gmbh Transfer von mRNAs unter Verwendung von polykationischen Verbindungen
JP2004509604A (ja) * 2000-03-28 2004-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド mRNAプロセッシングのアンチセンスモジュレーションによる、細胞行動の改変
EP1286699A2 (en) * 2000-05-19 2003-03-05 Regents Of The University Of Minnesota Composition for delivery of compounds to cells
EP1478751A4 (en) 2001-03-30 2005-10-19 Avigenics Inc LYSOZYM PROMOTER IN BIRDS
US7176300B2 (en) 2001-03-30 2007-02-13 Avigenics, Inc. Avian lysozyme promoter
US7541512B2 (en) 2001-03-30 2009-06-02 Synageva Biopharma Corp. Avians containing a lysozyme promoter transgene
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7135562B2 (en) 2002-03-14 2006-11-14 University Of Cincinnati Avian iFABP gene expression controlling region
AU2003231048A1 (en) 2002-04-22 2003-11-03 Regents Of The University Of Minnesota Transposon system and methods of use
CN100369930C (zh) 2002-11-26 2008-02-20 Pdl生物制药股份有限公司 调节血管生成的α5β1整合素的嵌合的和人源化的抗体
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
EP1697399B1 (en) 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS A human cytotoxic t-lymphocyte epitope and its agonist epitope from the non-variable number of tandem repeat sequence of muc-1
NL1027479C2 (nl) * 2004-10-21 2006-05-01 Synvolux Ip B V Bescherming van biologisch actieve moleculen met behulp van amphifielen.
AU2006208084B2 (en) 2005-01-25 2012-07-26 Prolexys Pharmaceuticals, Inc. Quinoxaline Derivatives as Antitumor Agents
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
EP2111553B1 (en) 2007-01-24 2018-09-19 Carnegie Mellon University Optical biosensors
EP2222701B1 (en) 2007-12-06 2017-11-01 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2010096388A2 (en) 2009-02-18 2010-08-26 Carnegie Mellon University Quenched dendrimeric dyes for bright detection
PE20120815A1 (es) 2009-05-05 2012-07-08 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
CN108404123A (zh) 2010-01-15 2018-08-17 康奈尔大学 降低细胞内蛋白质水平的方法
CA2787628A1 (en) 2010-01-21 2011-07-28 Dana-Farber Cancer Institute, Inc. Context specific genetic screen platform to aid in gene discovery and target validation
US9995679B2 (en) 2010-05-25 2018-06-12 Carnegie Mellon University Targeted probes of cellular physiology
CA2800531C (en) 2010-06-02 2021-05-25 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
WO2012092299A1 (en) 2010-12-27 2012-07-05 Brown University Therapeutic and diagnostic methods involving biglycan and utrophin
HUE037613T2 (hu) 2012-03-29 2018-09-28 Novimmune Sa Anti-TLR4 antitestek és azok felhasználása
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
CA3139031A1 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
CA2892585C (en) 2012-12-03 2022-07-05 Novimmune S.A. Anti-cd47 antibodies and methods of use thereof
WO2015143194A2 (en) 2014-03-19 2015-09-24 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
EP4112070A1 (en) 2014-04-25 2023-01-04 Dana Farber Cancer Institute, Inc. Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof
TWI695011B (zh) 2014-06-18 2020-06-01 美商梅爾莎納醫療公司 抗her2表位之單株抗體及其使用之方法
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
WO2016057488A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
US10434177B2 (en) 2014-11-17 2019-10-08 Carnegie Mellon University Activatable two-component photosensitizers
CN107406503B (zh) 2014-11-18 2021-07-16 詹森药业有限公司 Cd47抗体、方法和用途
EP3411713B1 (en) 2016-02-05 2021-06-30 NanoView Biosciences, Inc. Detection of exosomes having surface markers
EP4302782A3 (en) 2016-03-15 2024-03-27 Mersana Therapeutics, Inc. Napi2b-targeted antibody-drug conjugates and methods of use thereof
RU2019104896A (ru) 2016-07-22 2020-08-24 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования
CA3035081A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
US20190233505A1 (en) 2016-09-06 2019-08-01 Dana-Farber Cancer Institute, Inc. Methods of treating or preventing zika virus infection
TW201825674A (zh) 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
CA3093330A1 (en) 2018-03-14 2019-09-19 Novimmune Sa Anti-cd3 epsilon antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proc. Natl Acad. Sci. Vol. 87:3410-3414 (1990. 5) *

Also Published As

Publication number Publication date
EP0666923A1 (en) 1995-08-16
AU2678092A (en) 1993-04-05
AU681997B2 (en) 1997-09-18
CA2116107A1 (en) 1993-03-18
JPH07500820A (ja) 1995-01-26
WO1993004701A1 (en) 1993-03-18
EP0666923A4 (en) 1995-01-20

Similar Documents

Publication Publication Date Title
KR100252547B1 (ko) 폴리-또는 올리고누클레오티드의 세포로의 표적화된 전달
US6030954A (en) Targeted delivery of poly- or oligonucleotides to cells
US20200263179A1 (en) Compositions and methods for inhibiting gene expression of lpa
JP4062365B2 (ja) 短い外部ガイド配列
KR0171210B1 (ko) 암치료용 항감작 올리고뉴클레오티드
JPH10506536A (ja) 安定化外部ガイド配列
WO1997033622A2 (en) Delivery of nucleic acids by porphyrins
HU215187B (hu) Eljárás az RNS funkcióját gátló genetikai egységek előállítására, és eljárás sejtekbe való bevitelükre
KR20140092921A (ko) 트랜스티레틴(TTR) 관련 질병을 치료하기 위한 RNAi 제제, 조성 및 그의 사용방법
JP2000506725A (ja) 細胞増殖の阻害
US20110008366A1 (en) Inhibition of versican with sirna and other molecules
HUE033978T2 (en) DBAIT and its applications
JP5429884B2 (ja) 内因性カイロミクロンを利用した、標的遺伝子の発現を抑制する核酸のデリバリーシステム
JPH09511382A (ja) 抗b型肝炎性ポリ及びオリゴヌクレオチド
JP2023514336A (ja) アポリポタンパク質C3(APOC3)iRNA組成物およびその使用法
TW202138559A (zh) 含類PATATIN磷脂酶結構域3(PNPLA3)iRNA組成物及其使用方法
Echevarría et al. Evaluating the impact of variable phosphorothioate content in tricyclo-DNA antisense oligonucleotides in a duchenne muscular dystrophy mouse model
JP2023546103A (ja) Angptl3を阻害するための新規のrna組成物および方法
EP1531181A2 (en) Therapeutic oligonucleotides targeting the human mdr1 and mrp genes
JPH06503714A (ja) 細胞内に導入されたポリヌクレオチドの長時間発現
JP2008522639A (ja) カゼインキナーゼ2アンチセンス療法
CN115176011A (zh) 用于抑制pcsk9的组合物和方法
JP2022513111A (ja) Angptl8を阻害するための新規のrna組成物および方法
AU686614B2 (en) Targeted delivery of genes encoding antisense polyribonucleotides
KR20200014320A (ko) Apcs의 발현을 억제하는 핵산

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee